Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab
Phase 2Monoclonal antibody
Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab is one of 37 small molecule programs targeting Pleural Mesothelioma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Pleural Mesothelioma
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPhase 3
Paraplatin
AAvyxa
Phase 3
Gemzar
Johnson & JohnsonPhase 2
Volrustomig
AstraZenecaPhase 3
Standard Chemotherapy
RochePhase 3
Libtayo
RegeneronPhase 2
Trexall
Alnylam PharmaceuticalsPhase 2
Adriamycin
PfizerPhase 2
Gleevec
NovartisPhase 2
Imfinzi
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- IIstituto Oncologico Veneto IRCCS